newsfilter
← Earnings
Earnings Releases·

Aardvark Therapeutics — Third Quarter 2026 Earnings Summary

  • Cash and short-term investments declined to $60.3 million as of September 30, 2026, from $73.9 million in June 2026, while the company projects existing resources will fund operations through 2027.
  • Net loss widened to $19.2 million for the quarter ended September 30, 2026, compared to $16.3 million in the prior year period, driven by a $1.9 million increase in research and development expenses to $15.7 million.
  • The FDA lifted the clinical hold on ARD-101 in October 2026 and agreed to an open-label trial at 200 mg twice daily, with clinical activities expected to resume in 2027 following an FDA meeting scheduled for Q1 2027.
  • The board appointed Dr. David Zhang as an independent director in October 2026, and cardiac safety studies indicated no QRS or QT interval prolongation at doses up to 400 mg BID.
Company
AARDVARK THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology